

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
 7096-102XX / 10103632

In Re Application Of: Akit LALVANI, et al.

JC08 Rec'd PCT/PTO 30 APR 2001

Serial No.  
 (unassigned)

Filing Date  
 April 30, 2001

Examiner  
 (unassigned)

Group Art Unit  
 (unassigned)

Title: TUBERCULOSIS DIAGNOSTIC TEST

Address to:

Assistant Commissioner for Patents  
 Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

09/830839

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.  
 7096-102XX / 10103632

In Re Application Of: Akit LALVANI, et al.

JC08 Rec'd PCT/PTO 30 APR 2001

 Serial No.  
 (unassigned)

 Filing Date  
 April 30, 2001

 Examiner  
 (unassigned)

 Group Art Unit  
 (unassigned)

Title: TUBERCULOSIS DIAGNOSTIC TEST

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0337 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

Dated: April 30, 2001

Signature

Robert Berliner, Esq.  
 Reg. No. 20,121  
 FULBRIGHT & JAWORSKI L.L.P.  
 865 South Figueroa Street, 29th Floor  
 Los Angeles, CA 90017

(213) 892-9200  
 (213) 680-4518 (fax)

CC:

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Docket Number (Optional) <b>7096-102XX / 703632</b>	Application Number (unassigned) <b>09/830839</b>
Applicant(s) <b>Akit LALVANI, et al.</b>	Group Art Unit
Filing Date <b>April 30, 2001</b>	

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
/NMM/		WO 98/23960	6/4/1998	PCT				
/NMM/		WO 95/01441	1/12/1995	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

/NMM/		BRANDT, L. et al.: "Key Epitopes on the ESAT-6 antigen Recognized in Mice During the Recall of Protective Immunity to Mycobacterium tuberculosis." J. IMMUNOL., vol.196, no.157, 1996, pages 3527-3533
		HARBOE, M. et al.: "B-Bell Epitopes and Quantification of the ESAT-6 Protein of Mycobacterium tuberculosis" INFECT. IMMUN., vol.66, no.2, February 1998, pages 717-723
/NMM/		PATHAN, A. et al.: "Human T-Cell Responses to the Antigen ESAT-6 Characterize a Bacine Candidate and Potential Diagnostic Test for Tuberculosis." IMMUNOLOGY, vol.95, no. SUPPL. 1, December 1998, page 90
		PATHAN, A., et al.: "Identification of Conserved CD8+ Cytotoxic T Cell Epitopes in ESAT-6, a Tuberculosis Vaccine Candidate." IMMUNOLOGY, vol.95, no. SUPPL. 1, December 1998, page 108

EXAMINER <b>/N.M.Minnifield/</b>	<b>07/24/2009</b>	DATE CONSIDERED
-------------------------------------	-------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

7096-102XX / 103632

Application Number

(unassigned)

Applicant(s)

Akit LALVANI et al.

09/830839

Filing Date

April 30, 2001

Group Art Unit

\*EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/NMM/

ULRICH, T. et al.: "Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors." EUR. J. IMMUNOL., vol.28, no.12, December 1998, pages 3949-3958

/NMM/

ELHAY, M.J. et al.: "Delayed-Type Hypersensitivity Responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the Guinea Pig." INFECT IMMUN. vol.66, no.7, July 1998, pages 3454-3456

/NMM/

International Search Report, April 19, 2000, PCT/GB99/03635 International filing date Nov. 3, 1999

EXAMINER

/N.M.Minnifield/ 07/24/2009

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.